NewcelX Ltd. announced the peer-reviewed publication in Clinical Drug Investigation supporting Mazindol IR/SR, strengthening the scientific positioning of Mazindol ER under its CVR framework. The Company is engaged in advanced discussions with multiple counterparties for potential licensing and acquisition transactions to optimize CVR value.
Key takeaways
Peer-reviewed publication titled 'Mazindol Immediate-Release/Sustained-Release (IR/SR): A 50-Year Legacy of Multifaceted Mechanisms and Emerging Therapeutic Potential' published in Clinical Drug Investigation (DOI: https://doi.org/10.1007/s40261-025-01510-2)
Publication validates Mazindol ER's clinical and mechanistic profile for CVR-linked asset disposition
NewcelX engaged in advanced discussions with multiple counterparties for Mazindol ER licensing or acquisition
Mazindol ER intellectual property dates back to 2006, targeting narcolepsy, ADHD, and substance use disorders
Publication authored by international group of experts, reflecting over 20 years of research
Discussions conducted in structured competitive framework to maximize CVR value realization